Abstract | The immune system probably evolved to limit the negative effects exerted by pathogens on host homeostasis. This defence strategy relies on the concerted action of innate and adaptive components of the immune system, which sense and target pathogens for containment, destruction or expulsion. Resistance to infection refers to these immune functions, which reduce the pathogen load of an infected host as the means to preserve homeostasis. Immune-driven resistance to infection is coupled to an additional, and arguably as important, defence strategy that limits the extent of dysfunction imposed on host parenchymal tissues during infection, without exerting a direct negative effect on pathogens. This defence strategy, known as disease tolerance, relies on tissue damage control mechanisms that prevent the deleterious effects of pathogens and that uncouples immune-driven resistance mechanisms from immunopathology and disease. In this Review, we provide a unifying view of resistance and disease tolerance in the framework of immunity to infection. NATURE REVIEWS | IMMUNOLOGY VOLUME 17 | FEBRUARY 2017 | 83 REVIEWS © 2 0 1 7 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d .
. Clinical signs and symptoms of infectious diseases emerge as host homeostasis becomes compromised because of tissue dysfunction and damage [1] [2] [3] . Current understanding of this pathological process is limited, presumably impairing the ability to treat some infectious diseases that remain associated with high human morbidity and mortality 4 . Immunity provides general protection against disease and particularly against infectious diseases 4 . This is achieved by virtue of immune-driven resistance mechan isms that expel, contain or kill pathogens as the means to preserve host homeostasis. Therapeutic approaches based on the induction of immune-driven resistance mechanisms, such as vaccination, have proven highly protective against a broad range of infectious diseases 4 . The same is true for the use of antimicrobial agents, such as antibiotics, which functionally mimic resistance mechanisms by containing or killing pathogens 4 . The overwhelming therapeutic success of these approaches has probably contributed to the perception that resistance mechanisms are the only relevant defence strategy against infectious diseases. This idea has been challenged over the past years by the (re)discovery of disease tolerance 5, 6 . This evolutionarily conserved host defence strategy was originally revealed in plants through the recognition that variation in disease severity can occur at a population level without a direct correlation to pathogen load 7, 8 . However, it is now clear that disease tolerance is fully operational in animals, including flies 9, 10 , rodents 11, 12 and humans 13 , in which it preserves host homeostasis in response to viral 14, 15 , bacterial [15] [16] [17] [18] , fungal 19 and protozoan 11, 13, 20, 21 infections. In contrast to resistance to infection, disease tolerance does not exert a direct negative effect on these pathogens 6 
. Disease tolerance is now widely studied in experimental models of infection, in which the relationship between host health and pathogen load can be established at an individual level (BOX 2) . In this Review, we discuss the cellular and molecular mechanisms establishing disease tolerance to infection, and we explore the effects exerted by bona fide immunity on those mechanisms. We also highlight how symbiotic interactions with microorganisms and their regulation by specific components of innate and adaptive immunity affect disease tolerance to infection 22 . Finally, we suggest that the mechanisms underlying disease tolerance to infection can be therapeutically targeted.
Tissue damage control
The mechanisms underlying disease tolerance remain poorly understood but seem to revolve around several evolutionarily conserved stress and damage responses that confer tissue damage control in the infected host [1] [2] [3] ( FIG. 1) . These stress and damage responses sustain the functional outputs of host parenchymal cells under different forms of stress and damage imposed either directly by pathogens, that is, virulence, or indirectly by host immune-driven resistance mechanisms, that is immunopathology 1, 3 . Stress and damage responses provide metabolic adaptation and repair damage to cellular metabolites, macromolecules and/or organelles, as the means to preserve core cellular, tissue and organ functions required to preserve or restore host homeostasis. However, this often has detrimental effects on accessory cell functions, and as such stress and damage responses must be tightly regulated 1, 3 . When these responses fail to sustain the functional outputs of parenchymal cells, tissues or organs, the default programme becomes programmed cell death (FIG. 1) . This is coupled to the induction of cellular and tissue regenerative responses that have the capacity to restore the functional output of damaged parenchymal tissues or organs 3, 23 . As discussed in further detail below, different types of infection impose distinct forms of stress and damage, which suggests that tissue damage control mechanisms might function in a somewhat pathogen class-specific manner that reflects these differences to effectively establish disease tolerance against diverse types of infection 6 . Although there are obvious parallels between the protective effect exerted by tissue damage control mechanisms in the context of infectious and non-infectious diseases 1, 6, 24 , we focus our discussion on infectious diseases.
Stress responses in tissue damage control
Stress responses are triggered through the engagement of specific sensors that continuously monitor different physiological parameters under homeostatic regulation such as temperature, O 2 , pH, osmolarity, glucose and ATP [1] [2] [3] . When these parameters change beyond a certain threshold, 'stress sensors' set off signal transduction pathways that alert cells of a possible disruption to homeostasis [1] [2] [3] . The ensuing stress responses provide metabolic adaptation in host cells, which confers tissue damage control and contributes to the establishment of disease tolerance to infection [1] [2] [3] (FIGS 1,2). Signal transduction pathways triggered upon recognition of pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) by pattern recognition receptors (PRRs) can also contribute to tissue damage control and to the establishment of disease tolerance to infection 25 , which has been reviewed elsewhere 24, 26 and is not discussed in this Review. Instead, we focus on several bona fide stress responses as tissue damage control mechanisms that contribute to the establishment of disease tolerance to infection [1] [2] [3] .
Oxidative stress. The oxidative stress response controlled by the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) 27, 28 (FIG. 2) is important for the establishment of disease tolerance to systemic infections such as malaria 20, 29 . Briefly, the blood stage of Plasmodium spp. infection, the causative agent of malaria, is associated with haemolysis and hence with generation of extracellular haemoglobin 20, 21, 29, 30 . Upon oxidation, extracellular haemoglobin releases its prosthetic haem groups, which can function as catalysts in the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS). This can lead to oxidative stress and cellular damage of host parenchymal tissues 12, 13, 16, 31 , which in turn drive the pathogenesis of severe forms of malaria 30 . Genetic polymorphisms selected through human evolution on the basis of their protective effect against malaria, such as sickle mutations in the β-chain of haemoglobin, function via a NRF2-dependent mechanism that counteracts the pathogenic effects of labile haem and establish disease tolerance to the blood stage of Plasmodium spp. infection 20, 30, 32 . Activation of NRF2 is also protective against polymicrobial 33 and Staphylococcus aureus 34 infections, but whether this is due to the establishment of disease tolerance is unclear. However, the following two observations suggest that disease tolerance could indeed have a role: NRF2 polarizes macrophage responses towards the promotion of tissue damage control 35, 36 , and NRF2 induces mitochondrial biogenesis in parenchymal cells 34 , which probably also contributes to tissue damage control and disease tolerance to infections.
Hypoxia. Infections can be associated with a local or systemic decrease in O 2 supply to host cells, a condition known as hypoxia. This is sensed and countered by host cells via a stress response controlled by the hypoxia inducible factor (HIF) family of transcription factors 37 (FIG. 2) . Whether HIF activation in parenchymal cells
Box 1 | Tolerance and disease tolerance
There is a growing interest in understanding disease tolerance, both at a mechanistic level and its potential therapeutic application. However, the concept of disease tolerance and its associated terminology can easily be misinterpreted, probably because tolerance is broadly used to define some core properties of the immune system.
Immunological tolerance is an active process through which specific antigens become non-immunogenic -that is, fail to trigger adaptive immunity in a given individual -on the basis of immunoregulatory mechanisms that eliminate or suppress the activation and proliferation of antigen-specific B and T cells 123 . Immunological tolerance can explain immune discrimination between self and non-self, which is a concept deeply rooted in the understanding of immunity. Although some of the mechanisms regulating immunological tolerance and disease tolerance are functionally related, these two phenomena are clearly distinct.
Tolerance is also used to describe how innate immune cells, particularly macrophages, modulate responses to bacterial lipopolysaccharide (LPS). The cellular and molecular bases for LPS tolerance have been extensively studied and relate primarily to the induction of epigenetic modifications in enhancers, which modulate gene transcription in response to Toll-like receptor 4 (TLR4) signalling 124 . This is not specific to TLR4, as it can occur downstream of other pattern recognition receptors (PRRs) 125 and other sensors 18 . In some instances this response -which is referred to as 'trained immunity' (REF. 126 ) -has been functionally linked to the induction of disease tolerance 18 . Tolerance also refers to a related phenomenon in which exposure to a sub-lethal dose of a given agonist renders cells, tissues, organs or organisms tolerant to a subsequent higher dosage of the same substance that would otherwise be deleterious. This adaptive response -which is also referred to as hormesis or adaptation -relies on the activation of several evolutionarily conserved genetic programmes that confer protection against these agonists. Some of these genetic programmes overlap with those regulating stress and damage responses conferring tissue damage control and disease tolerance to infections 1, 3 . We use the term disease tolerance to refer explicitly to the same concept defined more than a century ago in the plant literature 5, 6 , in which disease tolerance defines a defence mechanism that limits 'damage to functions and structures' (REF. 8 ) imposed upon the host during an infection, without interfering with pathogen load 5, 6 . Of note, although disease tolerance by definition is not associated with modulation of pathogen load, it is possible that this response has an effect on pathogen physiology that is not revealed by corresponding changes in pathogen load.
contributes to the establishment of disease tolerance to infection has not been established, but HIF activation in macrophages provides metabolic adaptation towards ATP production via anaerobic glycolytic metabolism and modulates macrophage polarization 38, 39 towards an effector response that promotes tissue damage control and disease tolerance to infection 39, 40 , for example, in the context of Helicobacter pylori infection in mice 40 .
Metabolic stress. Some stress sensors directly or indirectly monitor variations in the relative concentration of essential metabolites such as ATP or glucose, respectively 1, 3 . These activate stress responses that adjust host cellular metabolism to the relative availability of the metabolites sensed (FIG. 2) . In strong support of the idea that metabolic stress responses can substantially contribute to the establishment of disease tolerance to infection is the finding that regulation of host glucose metabolism is essential to establish disease tolerance to viral and bacterial infections in mice 41 .
Osmotic stress. Systemic infections can be associated with osmotic stress 42 , which is sensed and counteracted by osmotic stress responses, such as the one regulated via the activation of nuclear factor of activated T cells 5 (NFAT5) 43 (FIG. 2) . This osmotic stress response acts in a cytoprotective manner in parenchymal cells 44 , conferring tissue damage control in the kidney during systemic polymicrobial infections 45 and probably in the heart during infection with coxsackievirus 46 in mice (FIG. 2) .
Damage responses and tissue damage control
When cellular stress associated with a given infection persists in strength and/or time, metabolic adaptation is no longer sufficient to preserve core cellular functions in the parenchymal tissues and organs that sustain homeostasis. The ensuing damage inflicted to cellular metabolites or macromolecules such as DNA, proteins and lipids, and eventually to organelles, activates specific damage responses that contribute to tissue damage control and to the establishment of disease tolerance to infection 1-3 (FIGS 1,2).
Metabolite damage and extracellular release. Metabolite damage refers to modifications of metabo lites that compromise their original function 47 . Such modified metabolites can have pathological effects via the impairment of host cellular functions and the generation of toxic products that promote inflammation, cellular stress and damage 47 . For example, sustained modifications of soluble As most studies investigating mechanisms of host protection against infection are not designed to detect the effect of disease tolerance, it is often difficult to disentangle disease tolerance from resistance to infection. When designing experimental approaches to identify mechanisms that regulate disease tolerance, one should consider quantifying physiological parameters that assess host homeostasis, such as temperature, oxygen, pH, osmolarity or glucose concentrations. However, these physiological parameters only reveal indirect disruptions of host homeostasis, a limitation resolved by direct quantification of parameters that estimate the function of tissues and organs such as brain, cardiovascular system, lungs, kidney and liver. When these parameters are plotted against host pathogen load, they can reveal variations in disease tolerance. Of note, these parameters should also be quantified at steady state -that is, before infection -so that host vigour -that is, health status before infection -can be defined. When these parameters cannot be quantified, incidence of mortality can be used to reveal irreversible homeostasis breakdown 13, 16, 17, 20 . The pathogen load of the infected host should ideally be quantified throughout the course of infection, for example, by sampling tissues in which pathogens accumulate, such as blood in malaria, lungs in pneumonia, liver in hepatitis, and so on. However, a potential bias of this approach is that it does not account for changes in pathogen behaviour, which can be reflected by variations in tissue tropism and accumulation at alternative sites. An alternative approach is to quantify pathogen load in the whole body, as routinely done when infecting flies 5, 9, 10, 127 . This is more challenging in other species such as rodents, but it can be achieved using transgenic pathogens expressing reporter genes that can be quantified throughout the course of an infection by whole-body imaging 29 . Disease tolerance is mostly inferred from how a host reacts to infection, which is inferred from the phenotype, that is, disease severity, produced by a given genotype under a certain pathogen load 5, 11, 128, 129 . In this analysis of host response to infection -also known as reaction norm analysis -each individual (genotype) is represented by a single health parameter and a pathogen load value, which corresponds to the ratio of minimum health parameter to maximum pathogen load 5, 11, 128, 129 . However, these reaction norms do not provide information on how the relationship between phenotype and pathogen load varies over time 129 . An alternative approach is to plot disease parameters versus pathogen load over time 130 . This approach enables mapping of disease trajectories, which are revealed by the concomitant changes in disease and pathogen load over time 130, 131 . The data from these fitness curves can potentially be used to estimate individual variations in disease tolerance 130, 131 .
Ataxia-telangiectasia mutated kinase
(ATM kinase). A serine and threonine protein kinase that is recruited and activated by DNA double-strand breaks and that has an important role in the activation of DNA damage responses.
Necroptosis
A specific form of programmed cell death mediated via a genetically encoded mechanism involving receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and RIPK3 and the mixed lineage kinase domain-like (MLKL) pseudokinase.
Ferroptosis
Genetically encoded form of programmed cell death driven by loss of activity of the lipid repair enzyme glutathione peroxidase 4 (GPX4) and by the accumulation of lipid hydroperoxides.
metabolites that promote their phase transition into crystals are sensed by PRRs, which can trigger inflammatory responses that are deleterious to the host 48 . Thus, limiting the pathological effects of metabolite damage can promote disease tolerance to infection (FIG. 2) .
Lipid damage. Lipid peroxidation can impair cellular membrane function, which eventually leads to the release of intracellular content 49, 50 (FIG. 2) . Moreover, sensing of lipid peroxidation products by PRRs 50 , such as Toll-like receptor 4 (TLR4), can exacerbate tissue damage, as shown during pathogenesis of influenza virus infection 51 . Expression of phospholipid hydroperoxide glutathione peroxidase 4 (GPX4) has a central role in inhibiting lipid peroxidation 28, 52 . This salutary effect occurs via a mechanism that relies on glutathione supply from an NRF2-regulated pathway involving solute carrier family 7 member 11 (SLC7A11; which together with SLC3A2 encodes the cystine/glutamate antiporter), glutamate-cysteine ligase catalytic subunit (GCLC), glutamate-cysteine ligase modifier subunit (GCLM, which encodes the γ-glutamylcysteine synthetase γGCS) and GSS (encoding the glutathione synthetase) 28, 52 . This suggests that activation of the transcription factor NRF2 contributes to counter lipid peroxidation via a mechanism that supports GPX4 activity. Haem catabo lism by the NRF2-regulated haem oxygenase 1 (HO1) also contributes to prevent lipid peroxidation 31 
(FIG. 2).
Proteotoxic damage. Proteotoxic damage responses aim to repair or eventually to degrade unfolded nascent or mature proteins as a means to preserve essential cellular functions 53, 54 . These can function as tissue damage control mechanisms and promote the establishment of disease tolerance to bacterial infection 53, [55] [56] [57] [58] (FIG. 2) . Of note, proteotoxic damage responses are also involved in the regulation of immune-driven resistance mechanisms against intracellular bacteria and viruses, some of which in turn evolved to modulate these responses as a strategy to repress host resistance 53, 59 . DNA damage. Infections are associated with host DNA damage and consequently with the activation of DNA damage responses 60 (FIG. 2) . This probably occurs via a mechanism involving the MRE11-RAD50-NBS1 complex, which activates ataxia-telangiectasia mutated kinase (ATM) -a master regulator of the doublestranded DNA damage response 61 . Activation of ATM confers tissue damage control and disease tolerance to polymicrobial infections in mice 17 , which suggests that DNA damage responses contribute to maintain both the genetic integrity and the functional outputs of parenchymal cells during infection.
Damage to cellular organelles. Autophagy is an evolutionarily conserved damage response that supports cell function under stress conditions that elicit damage to cellular organelles 62 (FIG. 2) . Autophagy regulates inflammatory responses and modulates disease tolerance to infections caused by pathogens such as Sindbis virus 63 and S. aureus 64 as well as to polymicrobial 17 infections in mice. Of note, autophagy can also function as a resistance mechanism against intracellular pathogens, so called xenophagy 62 .
Cell death in tissue damage control
When stress and damage responses fail to preserve cellular functional outputs, the default response is, in most cases, programmed cell death (FIG. 1) . Different forms of stress and damage are associated with distinctive forms of programmed cell death and ensuing pathophysio logi cal consequences 65 . For example, failure to resolve oxidative stress can lead to necroptosis 66 and failure to repair lipid peroxidation induces ferroptosis 67 . Irreparable DNA damage results in the induction of different programmed cell death pathways, including apoptosis 68 , which is regulated by the caspase family of cysteine proteases.
Although programmed cell death can damage host parenchymal tissues and lead to organ dysfunction, this relationship is not always straightforward because programmed cell death is also part of a resistance mechanism against intracellular pathogens 69 . However, the trade-off of this resistance mechanism can be particularly high, depending on the relative capacity of different tissues to withstand cell loss without compromising tissue function and homeostasis 6 . The pathophysiological relevance of Nature Reviews | Immunology Immunity exerts a negative effect on pathogens and triggers stress and damage in host parenchymal tissues, which can lead to cytotoxicity, tissue dysfunction and disease. Tissue damage control mechanisms involve several stress and damage responses that function in a concerted manner to protect parenchymal cells and tissues from dysfunction or damage caused by pathogens or by immune-driven host resistance mechanisms. Tissue damage control initially relies on stress responses that rewire metabolic pathways as the means to preserve the core functional outputs of parenchymal cells 1, 3, 151 . If stress persists over time, damage to intracellular metabolites, macromolecules and cellular organelles develops 1 . This activates damage responses that repair these different types of damage to preserve core functional outputs of parenchymal cells. Programmed cell death is triggered if this second layer of tissue damage control fails to preserve the functional outputs of parenchymal cells. When this occurs, the last layer of tissue damage control becomes cellular regeneration and tissue repair. If this still fails to preserve or to restore the functional outputs of parenchymal cells, the outcome is tissue dysfunction and damage, which is revealed by the appearance of the clinical signs and symptoms of infectious diseases. Immune responses regulate stress, damage and regenerative responses that underlie tissue damage control mechanisms and that contribute to the establishment of disease tolerance to infection.
this defence strategy is supported by the realisation that intracellular pathogens evolved a range of mechanisms that can modulate host genetic programmes controlling programmed cell death, presumably as a strategy to escape resistance to infection 70 . Programmed cell death of infected cells is coupled to phagocytosis by bystander macrophages or dendritic cells (DCs), which present pathogen-associated antigens to CD4 + T helper (T H ) cells or CD8 + cytotoxic T lymphocytes (CTLs) and thereby elicit an antigen-specific adaptive immune response that targets and kills the remaining reservoir of infected cells. Clearance of damaged and dying cells is associated with macrophage polarization towards the production of cytokines and lipid mediators that limit the extent of inflammatory reactions 71 . These include interleukin-10 (IL-10) and 15-deoxy-Δ-prostaglandin J 2 (15d-PGJ 2 ), which induce the expression of HO1 (REFS 72, 73) . Haem catabolism by HO1 modulates macrophage responses towards inhibition of pro-inflammatory gene expression 74 and probably exerts cytoprotective effects in bystander cells 75 . This proresolving response is also associated with the production of growth factors, such as platelet-derived growth factor (PDGF), and cytokines, including transforming growth factor-β1 (TGFβ1), which can directly affect parenchymal cells to promote tissue regeneration, regulating yet another layer of tissue damage control 23 . Although some tissue damage control mechanisms function in a cell-autonomous manner, other mechanisms seem to rely on bystander innate and adaptive immune cells. As discussed in the section below, tissue-resident leukocytes probably have a predominant role in this non-cell autonomous mechanism of establishment of disease tolerance to infection.
Immune regulation of tissue damage control
In this section we discuss how tissue-resident macrophages, innate lymphoid cells (ILCs) and regulatory T (T reg ) cells affect tissue damage control mechanisms and thereby contribute in a non cell-autonomous manner to the establishment of disease tolerance to infection (FIG. 3) . Figure 2 | Relative contribution of stress and damage responses to the establishment of disease tolerance to infection. Pathogen-derived toxins, such as pore-forming toxins, can function as a major driving force in the pathogenesis of infectious disease by inducing stress and damage to host cells, which eventually leads to programmed cell death 152 . Production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) by macrophages or polymorphonuclear cells is a common host immune resistance mechanism against various pathogens 153, 154 , which can lead to oxidative stress 153, 154 . This is sensed by Kelch-like ECH-associated protein 1 (KEAP1) 27, 28 -which under homeostatic conditions constitutively promotes the ubiquitylation and proteolytic degradation of the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) 27, 28 . Both ROS and RNS repress KEAP1 activity and enable NRF2 activation, which triggers the expression of effector genes regulating oxidative stress responses 27, 28 . Hypoxia is counteracted by a stress response triggered by the O 2 sensor prolyl hydroxylase domain protein 2 (PHD2) 37 , which constitutively represses the activity of the hypoxia inducible factor (HIF) family of transcription factors, under normoxic conditions 37 . HIF activation can also occur under normoxic conditions 37 , in response to pattern recognition receptor signalling, reduced intracellular iron availability or ROS. Hence, HIF activation might confer metabolic adaptation to different types of stress associated with infection 37 . Metabolic stress resulting from reduced intracellular ATP content is sensed and countered by a metabolic stress response controlled by AMP-activated protein kinase (AMPK) 155 . Metabolic stress resulting from a systemic reduction in glucose concentration is sensed indirectly by insulin receptor 156 . When insulin levels drop, phosphoinositide 3-kinase (PI3K) and AKT activation are reduced, promoting the activation of the forkhead box O (FOXO) family of transcription factors 156 . Activation of FOXO family members functions in a tissue-specific manner to promote or to repress disease tolerance to infection. For example, FOXO activation in epithelial cells regulates the expression of genes encoding antimicrobial peptides 157 and antioxidant enzymes 158 , which contribute to maintain epithelial barrier integrity and as such are protective against infection in flies 157,158 and mice 159 . Conversely, activation of FOXO1 and FOXO3α in muscle cells promotes myofibre atrophy and muscle wasting associated with sepsis in mice 160 and Mycobacterium marinum infection in flies 127 . Osmotic stress can be sensed by inflammasomes 161, 162 , containing NLRP3 (NOD-, LRR-and pyrin domain-containing 3) or NLRC4 (NOD-, LRR-and CARD-containing 4) 162 as well as by the A-kinase anchor protein 13 (AKAP13), which activates nuclear factor of activated T cells 5 (NFAT5) 43 , a transcription factor that provides metabolic adaptation to osmotic stress and confers tissue damage control during infection 45 . Metabolite damage, such as imposed by phase transition into crystals, functions in a pro-inflammatory manner as shown, for example, for uric acid-driven monosodium urate crystals 163 or cholesterol crystals 164 . This is sensed by NLRP3 inflammasomes, triggering a downstream signal transduction pathway, which involves the apoptosis-associated speck-like protein containing a CARD (ASC), caspase 1 and interleukin-18 (IL-18) 48 . Extracellular release of metabolites, such as ATP, is sensed by the P2X purinergic receptor 165 , which signals via inflammasomes 161 to promote inflammation and tissue damage 165 . This is countered by the catabolism of extracellular ATP and ADP into AMP and adenosine by CD39 and CD73, respectively 165 , which exert immunoregulatory effects, promoting the establishment of disease tolerance to Toxoplasma gondii 166 or Helicobacter spp. 167 infections in mice. Presumably these effects are mediated via adenosine-driven signalling through transmembrane adenosine G protein-coupled cell surface receptors 110, 168 . Lipid peroxidation is counteracted by several damage responses 49 including the induction of haem oxygenese 1 (HO1) 31 , which promotes the establishment of disease tolerance to bloodstream infections 16, 20, 21, [29] [30] [31] . Whether inhibition of lipid peroxidation by the glutathione-glutathione peroxidase 4 (GPX4) pathway also promotes disease tolerance to infection has not been established. Damage to proteins or proteotoxic damage is sensed by heat shock proteins, which activate heat shock factor 1 (HSF1) 54 , and is sensed in the endoplasmic reticulum by the 78 kDa glucose-regulated protein (GRP78) chaperone and inositol-requiring protein 1 (IRE1) 53 , which activate the unfolded protein response (UPR). HSF1 activation confers a survival advantage against Enterococcus faecalis and Pseudomonas aeruginosa infections in Caenorhabditis elegans 55, 56 and against Listeria monocytogenes infection in mice 57 . The UPR prevents immunopathology associated with P. aeruginosa infection in C. elegans 58 and preserves homeostatic control of microbiota interactions with the host gut epithelium 53 . The DNA damage responses controlled by Ataxiatelangiectasia mutated kinase (ATM) 17 and by p53 (REF. 169 ) confer tissue damage control and disease tolerance to pulmonary bacterial infections in mice. Damage to cellular organelles is counteracted by autophagy, which modulates disease tolerance to a variety of infections 17, [62] [63] [64] .
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Alarmins
Endogenous molecules released from damaged cells and sensed by receptors of the immune system that alert for tissue dysfunction or damage, associated with disruption of homeostasis.
Macrophages. Tissue-resident macrophages express high levels of PRRs and various other receptors that sense PAMPs, DAMPs or alarmins released from damaged cells, including cytokines that alert cells to the disruption of homeostasis 76, 77 (FIG. 3a) . These cytokines include IL-1α, IL-18 and IL-33, which polarize macrophages towards tissue-healing regenerative responses and, as discussed in the previous section, can contribute to the establishment of disease tolerance to infection (FIG. 3a) . Signalling via other sensors, such as the aryl hydrocarbon receptor (AHR) -a ligand-dependent transcription factor that senses exo genous environmental toxins and endogenous ligands -can also polarize macrophages towards the establishment of disease tolerance to bacterial infections 18 . Macrophage antimicrobial responses are associated with the expression of genes that can promote tissue damage control in parenchymal cells. These include inducible nitric oxide synthase (iNOS), which generates nitric oxide (NO), HO1, which generates carbon monoxide (CO), and cystathionine β-synthase (CBS), which generates hydrogen sulphide (H 2 S) (FIG. 3a) . These gasotransmitters 78 diffuse across cellular membranes to sense the metabolic status of microorganisms 79 while driving metabolic adaptation in host parenchymal cells 78, 80 , supporting tissue damage control and contributing to the establishment of disease tolerance to infection 13, 29 (FIG. 3a) .
Cytokines produced during these responses have a dual role, for example, tumour necrosis factor (TNF) can trigger programmed cell death and also activate pro-survival responses via activation of the nuclear factor-κB (NF-κB) family of transcription factors 81 (FIG. 3a) .
Phagocytosis is also associated with the production of ROS by macrophages, which supports stem cell division and differentiation towards tissue healing and Nature Reviews | Immunology -that alert cells to disruption of homeostasis. Signalling by these sensors polarizes macrophage responses to resolve inflammation and to assist parenchymal cells in restoring homeostasis 18, 170, 171 . This non cell-autonomous mechanism supporting tissue damage control is mediated by the production of gasotransmitters, including nitric oxide (NO), carbon monoxide (CO) and probably hydrogen sulphide (H 2 S), and by the secretion of cytokines, such as tumour necrosis factor (TNF), IL-6 and IL-10, and growth factors, including transforming growth factor-β (TGFβ) and members of the platelet-derived growth factor (PDGF) family. b | Tissue-resident innate lymphoid cells (ILCs) can sense alarmins, such as IL-33 and IL-1, via the corresponding ILRs or can sense cellular stress and damage via natural cytotoxicity receptors (NCRs) 85 . These trigger the production of cytokines such as IL-22 and epidermal growth factors (EGFs), including amphiregulin (AREG), which promote tissue damage control in parenchymal cells, such as epithelial cells 85, 86, 88 . c | Tissue-resident regulatory T (T reg ) cells sense alarmins, such as IL-18 and IL-33, which elicit the production of AREG [91] [92] [93] , affecting parenchymal cells to promote tissue damage control [91] [92] [93] and to establish disease tolerance to infection 92 . PCD, programmed cell death; PDGFR, PDGR receptor; EGFRs, EGF receptors; TCR, T cell receptor.
Nutritional immunity
An evolutionarily conserved resistance mechanism against infection based on the host's ability to withhold nutrients, such as iron, from pathogens. regeneration 82 . This process involves repression of the transcriptional programme activated by NRF2 (REF. 83 ), revealing a tight integration of stress and damage responses with subsequent tissue repair and regeneration programmes, which restore host homeostasis 23, 82, 84 (FIGS 1,2). How these apparently conflicting activities exerted by cytokines such as TNF or ROS are resolved remains to be understood 23 . This suggests, nevertheless, that antimicrobial macrophage responses have built-in feedback loops promoting tissue damage control.
Innate lymphoid cells. All three classes of ILCs, that is ILC1, ILC2 and ILC3, have a crucial role in sensing tissue dysfunction and damage, regulating tissue damage control responses 85 , which contribute to the establishment of disease tolerance to viral 86 and helminth 87 infections. These cells are also operational during intestinal inflammation 88 . For example, ILC2s can sense alarmins, such as IL-33, and promote tissue damage control in epithelia via a mechanism that involves the production of the epidermal growth factor (EGF)-like molecule amphiregulin 85, 86, 88 (FIG. 3b) . Natural cytotoxicity receptors (NCRs) expressed by ILC3s can sense ligands expressed by pathogens as well as self ligands upregulated in response to cellular stress 85 , which leads to the production of IL-22, an IL-10 family member that promotes epithelia repair and regeneration 89 (FIG. 3b) .
Regulatory T cells. Natural loss of function mutations
in the gene encoding the T reg cell lineage commitment transcription factor forkhead box protein P3 (FOXP3) are associated with development of severe immunopathology in both mice and humans 90 . This suggests that T reg cells contribute to tissue damage control and presumably therefore regulate the establishment of disease tolerance to infection. The physiological functions of T reg cells have mostly been assigned to their capacity to restrain adaptive and to a lesser extent innate immune responses 90 . More recently, tissue-resident T reg cells were shown to also promote tissue damage control mechanisms [91] [92] [93] , which can contribute to the establishment of disease tolerance to influenza virus infection 92 . This protective effect involves sensing of alarmins, such as IL-18 or IL-33, which elicits the production and secretion of amphiregulin 15, 91, 92 by tissue-resident T reg cells [91] [92] [93] (FIG. 3c) .
Whether this protective effect functions via direct interaction of tissue-resident T reg cells with parenchymal cells or indirectly through immunoregulatory mechanisms involving tissue-resident macrophages or ILCs has not been established (FIG. 3c) .
Stress and damage responses in immune cells. When exposed to different forms of infection-associated stress, tissue-resident macrophages, ILCs and T reg cells should activate the same stress and damage responses that operate in parenchymal cells to promote tissue damage control and disease tolerance to infection. For example, NRF2 activation in macrophages 35 or in T cells 94 exerts immunoregulatory effects that promote tissue damage control. Furthermore, activation of HIF1α in macrophages controls a metabolic response 39, 95 that shifts the balance between T H 17 and T reg cells 96 , and thereby modu lates immune-driven resistance and possibly disease tolerance to infection. Activation of other stress and damage responses in tissue-resident leukocytes probably exerts similar effects, but this is yet to be determined experimentally.
Pathogen-specific tissue damage control Multicellular organisms establish stable symbiotic interactions with a wide range of microorganisms, which affects different aspects of their physiology 97 and also modulates resistance and disease tolerance to pathogens 22 
. Infection by viruses, bacteria, fungi, protozoan parasites or helminths imposes distinct forms of stress and damage on host parenchymal cells that are driven by intrinsic differences in virulence mechanisms and countervailing host immune-driven resistance mechanisms elicited. Thus, tissue damage control mechanisms probably function in a pathogen-specific manner to confer disease tolerance to different types of infection, as originally shown in flies 98 and thereafter in mice 6, 99, 100 . In this section we discuss how immunedriven resistance to a specific pathogen class regulates tissue damage control mechanisms that contribute to the establishment of disease tolerance to pathogens within the same or other classes.
Intracellular pathogens.
Host resistance to intra cellular pathogens, such as viruses and certain bacteria, relies to a large extent on targeting infected cells for programmed cell death by type 1 immunity-driven cytotoxic mechanisms 101 (FIG. 4a) . Hence, tissue damage control mech anisms opposing type 1 immunopathology should not rely on cytoprotection of infected cells, as this would compromise resistance to intracellular pathogens. Instead, these tissue damage control mechanisms are more likely to promote cell regeneration and tissue repair as a means to compensate for loss of infected and bystander parenchymal cells, restoring tissue homeo stasis 15, 92 (FIG. 4a) . The mechanisms by which this occurs are not completely established but are probably tissue specific 6 and involve the production of EGF and PDGF family members as well as TGFβ, which promote stem cell proliferation and/or differentiation into parenchymal cells and thereby restore tissue integrity and function 23 (FIG. 4a) .
Extracellular parasites. Host resistance to extracellular metazoan parasites mainly depends on type 2 immunity 101, 102 . Some of these parasites are damaging to host parenchymal tissues, which presumably explains why type 2 immunity encompasses tissue damage control mechanisms that contribute to the establishment of disease tolerance 103 (FIG. 4b) . Type 2 immunity targets pathogens primarily for containment or expulsion, probably because of the inherent failure of most immune-driven cytotoxic molecules to kill large metazoan parasites such as helminths (FIG. 4b) . In addition, type 2 cytokines promote macrophage polarization towards granuloma formation and thereby contain pathogens and deprive them of essential nutrients. This resistance mechanism, known as nutritional immunity, is perhaps best illustrated by the modulation of host iron metabolism as a strategy to deprive pathogens of this essential nutrient 104 . Macrophage polarization by type 2 cytokines also deprives pathogens of access to other essential nutrients such as arginine, which is depleted via the expression of high levels of arginase in macrophages 105 . Arginine depletion also prevents sustained T cell activation and thereby limits immunopathology 105 . As a trade-off, nutritional immunity can impose metabolic stress on host parenchymal cells, thereby activating stress responses that confer meta bolic adaption and possibly tissue damage control and disease tolerance to extracellular parasites (FIG. 4b) .
Extracellular bacteria and fungi. Host resistance to pathogenic extracellular bacteria and fungi relies to a large extent on T H 17 immunity 101 .
Most of the immune
Box 3 | Microbiota and disease tolerance
There are numerous examples of symbiotic microorganisms that enhance resistance to infection in animals 22 . The bacterial endosymbiont Wolbachia, for example, enhances resistance to Drosophila C virus in flies 10, 132 and to dengue, chikungunya as well as Zika virus infections in mosquitoes 133, 134 (see the figure, part a) . This protective effect has been linked to priming of the insect innate immune system and possibly competition for resources supporting pathogen replication 135, 136 . Symbiotic interactions between bacteria and mice can also promote immune-driven resistance mechanisms against viral 137 , bacterial 138 or protozoan 139, 140 infections (see the figure, part a) . This suggests that the establishment of stable symbiotic interactions between microcellular and multicellular organisms is a widespread recurrent trait that modulates host resistance against a range of pathogens. Symbiotic bacteria can also modulate tissue damage control and disease tolerance to infection in multicellular organisms 10, 22, 141, 142 (see the figure, part b) . For example, Wolbachia enhance disease tolerance to flock house virus infection in flies 10 and against Plasmodium relictum infection in mosquitoes 142 . In mice, bacteria that colonize the gut -such as the human symbiont Bacteroides fragilis -confer disease tolerance to Helicobacter hepaticus infection 143 , whereas the gut symbiont Escherichia coli O21:H + confers disease tolerance to Burkholderia thailadensis or Salmonella enterica subsp. enterica serovar Typhimurium infections 141 (see the figure, part b).
Although the mechanisms by which endosymbiotic bacteria promote disease tolerance to viral infections in insects are not completely understood, some mechanistic insight is emerging in mice 22 . For example, the gut commensal E. coli O21:H + confers disease tolerance to systemic bacterial infections via a mechanism that involves the activation of the NLRC4 (NOD-, LRR-and CARD-containing 4) inflammasome, which induces the production of interleukin-18 (IL-18) 141 . This alarmin sustains the production of insulin-like growth factor 1 (IGF1), which activates the phosphoinositide 3-kinase (PI3K)-AKT signal transduction pathway and represses the expression of the E3 ubiquitin ligases atrogin 1 (also known as FBXO32) and MURF1 (also known as TRIM63) in muscle cells 141 . This prevents the development of muscle atrophy and the loss of body weight, which are common pathological outcomes of infection. Components of the microbiota can also modulate disease tolerance by altering the glycosylation profile of the gut epithelia lumen -as shown for regulation of fucose expression under inflammatory conditions -which modulates microbiota composition, metabolism and gene expression in a manner that promotes disease tolerance to enteric infection by Citrobacter rodentium 144 . Modulation of host metabolism by bacterial components of the microbiota 145 probably also modulates tissue damage control mechanisms and disease tolerance to infection 22 . Whereas bacterial symbionts such as Clostridium strains 146 can promote the development of regulatory T (T reg ) cells in mice, it is not clear whether this in turn modulates disease tolerance to infections.
In the same way that pathogens can modulate host resistance mechanisms, some pathogens can also promote disease tolerance as the means to support their own survival, proliferation and/or transmission. For example, S. Typhimurium induces the activation of host RHO GTPases and mitogen-activated protein kinases (MAPKs), which leads to the activation of nuclear factor-κB (NF-κB) and to the expression of downstream pro-inflammatory genes in the gut epithelium 147 . This activation enables S. Typhimurium to overcome immune-driven host resistance imposed by the resident gut microbiota 147 and promotes invasion of gut epithelial cells and systemic infection 148 . During bacterial invasion of the epithelium, S. Typhimurium secrete proteases that target the NF-κB family members RELA and RELB and inhibit the transcription of downstream pro-inflammatory genes 149 . This immunoregulatory effect limits tissue damage and disease severity without interfering with host pathogen load 149 ; thus, S. Typhimurium promotes disease tolerance to infection.
Another example of how bacteria can promote disease tolerance is the induction of IL-10 by Staphylococcus aureus 150 . Recognition of staphylococcal peptidoglycan by Toll-like receptor 2 (TLR2) induces IL-10, which prevents unfettered T cell activation; hence, the response to S. aureus infection promotes tissue damage control and disease tolerance to infection 150 . Nature Reviews | Immunology 101 . This can be associated with the development of immunopathology, as shown at epithelial barriers where ROS and elastase produced by neutrophils can cause epithelial cell damage and compromise disease tolerance to pathogenic Gram-negative bacteria, for example, in the case of infection with Burkholderia pseudomallei 106 (FIG. 4c) . T H 17 immunopathology is counteracted by tissue damage control mechanisms that protect epithelial barriers against oxidative stress and damage as well as by additional mechanisms that promote tissue repair and regeneration (FIG. 4c) . Some of these mechanisms are regulated directly or indirectly by IL-22 produced by T H 17 cells or by ILC3s, which signals via the IL-22 receptor expressed by epithelial cells 86, 88, 107 (FIG. 4c) .
Disease tolerance to co-infections Pathogen class-specific tissue damage control mechanisms are particularly relevant in the context of coinfections, as shown for bacterial pneumonia following influenza virus infection 108 . Several mechanisms may contribute to worsen the clinical outcome of these coinfections. Viral infections can compromise immunedriven resistance 99 or tissue damage control 15 mechanisms against bacterial co-infections, as is the case for influenza virus and Legionella pneumophila co-infections 15, 99 . This is probably also the case for co-infections by rhinovirus, adenovirus or parainfluenza and Streptococcus pneumoniae, as well as for Haemophilus influenza and Moraxella catarrhalis co-infections 108 . The mechanisms by which viruses compromise disease tolerance to secondary bacterial infections are probably multi-factorial and have been associated with the dysregulated production of EGF-like factors, such as amphiregulin 15 , by lung-resident ILCs 86 and T reg cells 92 . Immune-driven resistance mechanisms targeting viruses can also promote, rather than impair, disease tolerance to bacterial infections. For example, regulation of IL-1β-induced inflammation by type I interferon (IFN) prevents the lethality of systemic Streptococcus pyogenes infection, without affecting bacterial load 109 . In this case, signalling via type I IFN receptor in macrophages, DCs and neutrophils represses IL-1β transcription through signal transducer and activator of transcription 1 (STAT1), and to a lesser extent through STAT2, which ultimately prevents the development of lethal IL-1β-driven inflammation 109 . Disease tolerance against one class of pathogens has also been shown to antagonize immune-driven resistance against other pathogen classes. For example, the induction of HO1 expression promotes disease tolerance to the blood stage of Plasmodium spp. infection 12, 20, 21, 30 but impairs resistance to Salmonella enterica subsp. enterica serovar Typhimurium co-infection 100 . This is thought to involve dysregulated mobilization of granulocytes from the bone marrow with concomitant induction of HO1 during Plasmodium spp. infection, which reduces their subsequent capacity to generate ROS and to clear S. Typhimurium infection 100 .
Therapeutic modulation of disease tolerance
In some cases, effective pathogen elimination by immune-driven resistance mechanisms fails to overcome the morbidity or mortality associated with infection. Moreover, current antimicrobial approaches can also fail to treat infectious diseases. In these cases, a rational pharmacological targeting of stress and damage responses regulating tissue damage control may act therapeutically through the establishment of disease tolerance to infection. Examples of proof-of-concept for this approach are provided by pharmacological targeting of adenosine receptors 110 or labile haem 16 , which promote the establishment of disease tolerance to sepsis 16, 110 or malaria 20, 21, 30 in mice. When targeting labile haem, several pharmaco logical strategies can be envisioned. For example, administration of haemopexin -which is a plasma protein that binds avidly to labile haem and neutralizes its deleterious effects -confers tissue damage control and disease tolerance to sepsis in mice 16 . Gasotransmitters such as CO 21 can also be used pharmacologically to block haem-iron oxidation (Fe 2+ to Fe 3+ ) and inhibit haem release from haemoproteins, thereby preventing its accumulation in plasma during bloodstream infections 20, 21 . Remarkably, this is sufficient to confer disease tolerance to malaria in mice 20, 21, 30 . When used pharmacologically, the gasotransmitter NO also promotes the establishment of disease tolerance to malaria in mice 29 . This protective effect of NO occurs via an indirect mechanism involving the activation of the transcription factor NRF2, the induction of HO1 expression and the downstream generation of CO, which consequently establishes disease tolerance to malaria [29] [30] [31] . In addition to preventing haem release from extracellular haemoglobin, the cytoprotective effects of CO 75 should also contribute to promote tissue damage control and disease tolerance to malaria. As labile haem is a potent pro-oxidant, pharmacological use of antioxidants such as N-acetyl cysteine can prevent this pathogenic effect and thereby confer tissue damage control and disease tolerance to malaria 12, 13 . Moreover, downstream events in the signalling transduction pathways driving haem cytotoxicity, such as sustained activation of JUN amino-terminal kinases, can also be targeted pharmacologically to promote recovery and survival through tissue damage control during malaria infection 13 . Pharmacological targeting of metabolic stress responses, such as the one regulated by 5′ AMPactivated protein kinase (AMPK), confers protection against the development of organ dysfunction associated with the pathogenesis of sepsis in mice 111 . This treatment is not associated with overt modulation of the host pathogen load, which suggests that AMPK activation contributes to the establishment of disease tolerance to sepsis 111 . In further support of this idea, pharmacological AMPK activation in the brain is sufficient to confer protection against polymicrobial infections in mice 112 .
Another possible approach to modulate disease tolerance involves targeting the inflammatory response to infection without interfering with immune-driven resistance mechanisms. This can be achieved, for example, by pharmacological inhibition of topoisomerase 1, which suppresses the recruitment of RNA polymerase II to the promoter of PRR-responsive genes 113 . This approach confers a net survival advantage, presumably through the establishment of disease tolerance, against viral and bacterial infections as well sterile tissue injury in mice 113 . Pharmacological use of cytokines that are cytoprotective in parenchymal cells, such as IL-10 (REF. 114 ) and IL-22 (REF. 115 ), or that promote tissue regeneration, such as EGF-like factors, including amphiregulin 15, 92 , have also been shown to promote disease tolerance to infections in mice.
Furthermore, pharmacological targeting of specific host resistance mechanisms associated with the development of immunopathology is another therapeutic approach to establish disease tolerance to infection 116 . However, as a trade-off, this strategy can be associated with reduced host resistance and hence increased pathogen load, as shown for influenza A virus 117 and Nature Reviews | Immunology , in which cyclooxygenase inhibition using ibuprofen decreases both lung lesions and pathogen load. These, among other studies, provide the proof-of-principle that immunoregulatory mech anisms can be targeted pharmacologically to confer tissue damage control and disease tolerance to different types of infection when antimicrobial therapy alone fails to overcome host morbidity or mortality.
An important question to address is how to rationally design therapeutic approaches that would target tissue damage control mechanisms and confer disease tolerance to infection. One possible way forward is the use of functional 'drug screens' , which have already been successful in identifying anthracycline as a family of chemotherapeutic agents inducing disease tolerance to sepsis in mice 17 . The therapeutic effect of anthra cyclines was associated with the induction of tissue damage control via a mechanism involving the ATM kinase 17 . This and a subsequent study 113 suggest that targeting specific components of the host DNA damage response machinery has therapeutic potential in the establishment of disease tolerance to sepsis.
Finally, a few classes of antibiotics -macrolides, fluoroquinolones, tetracyclines and polymyxines -are labelled as immunomodulatory on the basis of their ability to improve the outcome of chronic disorders via mechanisms not readily explained by their antimicrobial activity 120 . Macrolides have the best-documented immuno modulatory activity; for example, the therapeutic effects of the macrolide azithromycin in cystic fibrosis can be dissociated from its antibacterial activity 120 . The immunomodulatory effect of these antibiotics probably goes beyond inhibition of pro-inflammatory mediators and other immune processes and could involve the modu lation of molecular pathways associated with the regulation of host lifespan. In support of this idea, tetracyclines increase longevity in Caenorhabditis elegans via a mechanism involving the unfolded protein response (UPR) 121 , which is a damage response that promotes disease tolerance to infections (as discussed above). Colistin induces the activation of the forkhead box O (FOXO) pathway, which is another lifespan extension pathway in C. elegans that confers disease tolerance to Gram-negative infections 122 . Of note, these antibiotics have not been shown to exert a direct effect on tissue damage control mechanisms and more definitive conclusions need to be experimentally confirmed, for example, by using germ-free organisms.
Concluding remarks and perspectives
It is now clear that multicellular organisms use two genetically distinct defence strategies to limit the pathogenicity of microorganisms. The prevailing view has long been that immune-driven host resistance mechanisms that contain, kill or expel invading microorganisms are the prevailing defence strategy against infectious diseases. However, disease tolerance is an equally important host defence strategy against infection, which does not have a direct negative effect on pathogens and functionally interacts with immune-driven resistance mechanisms to limit the severity of infectious diseases. The cellular and molecular bases of these interactions are only now starting to be appreciated. A series of experimental approaches have been used to identify and characterize the molecular and cellular basis of tissue damage control mechanisms conferring disease tolerance to various pathogens. These mechanisms have so far been restricted to numerous evolutionarily conserved stress and damage responses, which have in some cases been associated with immunoregulatory responses controlling host resistance mechanisms. How immuno regulatory mechanisms modulate these 
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. The T helper 1 (T H 1) signature cytokine interferon-γ (IFNγ) has a central role in triggering cytotoxic mechanisms that, although directed against intracellular pathogens, can lead to tissue damage through various means, including macrophage polarization towards an antimicrobial response associated with the production of high levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS), activation of CD8 + cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells to kill infected cells via the perforin and/or granzyme B-dependent lytic pathway or via the ligation of surface death receptors; and B cell activation towards the production of cytolytic antibodies that target infected cells for complement and Fc receptor-mediated cellular cytotoxicity. Tissue damage control mechanisms counteracting type 1 immunopathology rely on cellular regeneration and tissue repair to restore homeostasis 15, 92 . The mechanisms by which type 1 immunity contributes to this tissue damage control response are not clear but probably involve the production of epidermal growth factors (EGFs), transforming growth factor-β (TGFβ) and platelet-derived growth factor (PDGF), which drive the proliferation and differentiation of stem cells into functional parenchymal cells, restoring tissue integrity and function 23 . b | Resistance to extracellular metazoan parasites and other large parasites is mediated and/or involves type 2 immunity 101, 102 . Pathogen neutralization is achieved via different mechanisms controlled by T H 2 signature cytokines, including interleukin-4 (IL-4), IL-5 and IL-13, and by additional type 2 cytokines such as thymic stromal lymphopoietin (TSLP), IL-25 or IL-33, secreted by damaged cells 101, 102 . T H 2 signature cytokines drive B cell activation towards the production of high-affinity pathogen-specific IgG1 and IgE antibodies that function via Fc-dependent mechanisms to trigger the activation of eosinophils, mast cells and basophils, expelling pathogens across epithelia 102 . Some of these parasites, for example, helminths, are damaging to parenchymal cells and type 2 immunity encompasses tissue damage control mechanisms that confer disease tolerance to infection by these parasites 103 . These mechanisms involve the production of EGFs, vascular endothelial growth factor (VEGF), TGFβ, resistin-like molecule-α (RELMα) and RELMβ. c | T H 17 immunity confers resistance to extracellular bacteria such as Klebsiella pneumoniae, Escherichia coli, Citrobacter rodentium, Bordetella pertussis, Porphyromonas gingivalis and Streptococcus pneumoniae, and also to fungi such as Candida albicans, Coccidioides posadasii, Histoplasma capsulatum and Blastomyces dermatitidis . T H 17 immunopathology is driven to a large extent by products of neutrophil activation, such as ROS and elastase. This is countered by tissue damage control mechanisms regulated directly or indirectly by IL-22, originating from T H 17 cells, T H 22 cells (not shown) or ILC3s, and promoting tissue damage control. Other cytokines produced by T H 17 cells, including IL-17, can amplify this protective response, working together with fibroblast growth factor 2 (FGF2) produced by regulatory T (T reg ) cells to promote tissue damage control at epithelial barriers 172 . DC, dendritic cell; EGFR, EGF receptor; FGF2R, FGF2 receptor; IFNγR, IFNγ receptor; ILR, interleukin receptor; PCD, programmed cell death; PRR, pattern recognition receptor. ◀ stress and damage responses to confer disease tolerance to infection is fairly unexplored. A growing number of experimental evidence also suggests that symbiotic microorganisms can regulate disease tolerance to prevent their pathogenicity as well as that of other pathogens 22 . However, whether this regulation occurs via the induction of immunoregulatory mechanisms and/or the activation of stress and damage responses remains to be established. Deciphering the cellular and molecular nature of these interactions is crucial for understanding, and perhaps subsequently shaping, therapeutic strat egies to manipulate protection against major infectious diseases in which host resistance mechanisms fail to limit disease severity. Such therapeutic approaches will probably also be important to overcome the growing global health threat imposed by the emergence of multidrugresistant pathogens as well as to treat co-infections associated with high levels of morbidity and mortality.
